Modern clinical pharmacology approaches to negative symptom treatment in schizophrenia

Negative symptoms contribute to poor functional outcomes and quality of life for individuals with schizophrenia. Efficacy of negative symptom treatment in patients with schizophrenia are discussed by the example of a new atypical antipsychotic cariprazine (Reagila®). Discussion. Improved Receptor Profile: high affinity for D3 receptors and partial agonism for both dopamine receptor subtypes, may act as a basic mechanism for improving negative symptoms and cognitive impairment. Сonclusions. Сariprazine is the drug of choice in the treatment of adult patients both at the onset of the disease with a predominance of negative disorders, and in the chronic course of schizophrenia with positive and negative symptoms, especially in patients with a high risk of metabolic and cardiovascular disorders.